TITLE

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

AUTHOR(S)
Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard; Rønn, Birgitte Biilmann
PUB. DATE
June 2004
SOURCE
Diabetes;Jun2004, Vol. 53 Issue 6, p1614
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age 38 +/- 10 years [mean +/- SD], BMI 24 +/- 2 kg/m(2), HbA(1c) 7.5 +/- 1.2%, diabetes duration 18 +/- 9 years) participated in this parallel group comparison. Each subject received four single subcutaneous doses of 0.4 units/kg of either insulin detemir (n = 18), insulin glargine (n = 16), or human NPH insulin (n = 17) under euglycemic glucose clamp conditions (target blood glucose concentration 5.5 mmol/l) on four identical study days. The pharmacodynamic (glucose infusion rates [GIRs]) and pharmacokinetic (serum concentrations of insulin detemir, human insulin, and insulin glargine) properties of the basal insulin preparations were recorded for 24 h postdosing. Insulin detemir was associated with significantly less within-subject variability than both NPH insulin and insulin glargine, as assessed by the coefficient of variation (CV) for the pharmacodynamic end points studied [GIR-AUC((0-12 h)) 27% (detemir) vs. 59% (NPH) vs. 46% (glargine); GIR-AUC((0-24 h)) 27 vs. 68 vs. 48%; GIR(max) 23 vs. 46 vs. 36%; P < 0.001 for all comparisons]. Insulin detemir also provided less within-subject variability in the pharmacokinetic end points: maximal concentration (C(max)) 18 vs. 24 vs. 34%; INS-AUC((0- infinity )) 14 vs. 28 vs. 33%. The results suggest that insulin detemir has a significantly more predictable glucose-lowering effect than both NPH insulin and insulin glargine.
ACCESSION #
13262170

 

Related Articles

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Low-dose guar improves diabetic control. Jones, D. B.; Lousley, S.; Jelfs, R.; Slaughter, P.; Carter, R. D.; Mann, J. I. // Journal of the Royal Society of Medicine;Jul1985, Vol. 78 Issue 7, p546 

    Twenty diabetic outpatients (12 non-insulin-treated and 8 insulin-treated) were given guar granulate in a dose of 10 g daily for two months in order to study the effect on glycaemic control and lipid levels. Mean glycosylated haemoglobin levels (HbA1c%) fell from 1.1± 2.0% pre-guar to 10.5...

  • 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo. Pencek, R. Richard; Shearer, Jane; Camacho, Raul C.; James, Freyja D.; Lacy, D. Brooks; Fueger, Patrick T.; Donahue, E. Patrick; Snead, Wanda; Wasserman, David H. // Diabetes;Feb2005, Vol. 54 Issue 2, p355 

    The infusion of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) causes a rise in tissue concentrations of the AMP analog 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranotide (ZMP), which mimics an elevation of cellular AMP levels. The purpose of this work was to determine the...

  • Assessment of Beta-Cell Responsiveness by IVGTT in Patients with Type 2 Diabetes: an Exploratory Trial in Patients Who Have Substituted Exenatide for Insulin. Davis, Stephen; Johns, Don; Northrup, Justin; Maggs, David; Bhole, Deepak; Xu, Hangtao; Brodows, Robert // Diabetes;Jun2007 Supplement 1, Vol. 56, pA138 

    In this 16-week pilot study, we explored the safety of substituting exenatide (5 µg BID for 4 wks, 10 µg BID thereafter) for insulin in patients who were using insulin in combination with oral agents. Patients with type 2 diabetes were randomized to either substitute exenatide for insulin...

  • Importance of daily plasma glucose control in type 2 diabetes. Pollom, Roy Daniel // Journal of Family Practice;Aug2009 Practical Insulin Strat, Vol. 58 Issue 8, pS10 

    The article discusses the significance of daily plasma glucose control in type 2 diabetes. It explores the physiologic pattern of insulin secretion and type 2 diabetes abnormalities. It highlights the postprandial glucose as key determinants of outcomes in patients with type 2 diabetes and the...

  • Insulin granule dynamics in pancreatic beta cells P. Rorsman and E. Renström: Granule dynamics in insulin-secreting cells. Rorsman, P.; Renström, E. // Diabetologia;Aug2003, Vol. 46 Issue 8, p1029 

    Glucose-induced insulin secretion in response to a step increase in blood glucose concentrations follows a biphasic time course consisting of a rapid and transient first phase followed by a slowly developing and sustained second phase. Because Type 2 diabetes involves defects of insulin...

  • EVALUATION OF ANTI-DIABETIC POTENTIALS OF METHANOLIC EXTRACT OF FICUS MICROCARPA LEAVES IN ALLOXAN INDUCED DIABETIC RATS. RAVICHANDRA, V. D.; PAARAKH, PADMAA M. // International Journal of Pharmacy & Pharmaceutical Sciences;2013 Supplement, Vol. 5 Issue Supp 3, p369 

    Objective: The present study was designed to evaluate the acute and chronic effects of the extract against alloxan induced diabetic rats. Methods: In acute study, hypoglycemic potency of methanolic extract of Ficus microcarpa was assessed by oral glucose tolerance test (OGTT) and in chronic...

  • Daytime Variation in Postprandial Glucose and Pancreatic Beta-Cell Response in Persons with Type 2 Diabetes on Diet and Oral Hypoglycaemic Agents, with Varying Degrees of Glycaemic Control. Peter, Rajesh; Luzio, Stephen D.; Dunseath, Gareth; Chudleigh, Richard; Owens, David R. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA682 

    It has been previously suggested that glycaemic excursions in subjects with type 2 diabetes vary during the day, following identical meals. The aim of this study was to investigate, in subjects with different levels of HbA[sub 1c] differences in B-cell secretory patterns during the day in...

  • INSULIN GLARGINE IN GASTROSTOMY FEEDING. Isildak, S. M.; Ayturk, S.; Bascil, S.; Tutuncu, N. B. // Acta Endocrinologica (1841-0987);Apr-Jun2012, Vol. 8 Issue 2, p257 

    Context. For control of blood glucose in diabetic patients on enteral feeding either insulin infusion or multiple insulin injections are used. However, both of these methods necessitate a very close follow-up and are not easy to apply during home care. Objective. In this study we aimed to see...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics